Form 4: MiMedx Director James Bierman Receives Stock Grant

Director James L. Bierman acquired 50,913 shares of MiMedx Group, Inc. common stock as part of an annual restricted stock grant.

Summary

• Director James L. Bierman was granted 50,913 shares of common stock on June 10, 2026.
• The shares were issued at a price of $3.64 per share.
• Following this transaction, Mr. Bierman's total beneficial ownership increased to 263,684 shares.
• The grant is an annual restricted stock award for non-employee directors.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of market impact.

Positives

• Director alignment with shareholder interests is reinforced through increased equity ownership.
• The grant is part of a standard annual compensation structure for non-employee directors.

Negatives

• None identified.

Risks

• None identified.

Future Outlook

The restricted stock award vests upon the earlier of 12 months from the grant date or the next meeting of shareholders.

Industry Context

StockSavvy.ai notes that annual equity grants to non-employee directors are a standard corporate governance practice in the biotechnology and medical device sectors to ensure long-term alignment between board members and shareholders.

Comparison to Industry Standards

• The grant structure is consistent with standard equity compensation practices for directors in the healthcare sector.
• The vesting period of 12 months is standard for annual director equity awards among mid-cap medical technology companies.

Stakeholder Impact

• Shareholders benefit from increased director 'skin in the game'.

Next Steps

• Vesting of the 50,913 shares in 12 months or at the next shareholder meeting.

Key Dates

Keywords

MiMedx, MDXG, Director Stock Grant, Insider Transaction, Form 4